Trial Profile
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2019
Price :
$35
*
At a glance
- Drugs Enzaplatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Aviragen Therapeutics
- 02 Feb 2017 According to an Aviragen Therapeutics media release, safety results from this trial along with the other clinical data will form the basis for the interaction with the FDA to discuss lifting the clinical hold on BTA585s Investigational New Drug application.
- 01 Feb 2017 According to an Aviragen Therapeutics media release, company is planning to analyse the full data and report the plan for this program in the second quarter of 2017.
- 01 Feb 2017 Results published in an Aviragen Therapeutics Media Release